Floreo started raising capital earlier this year to get its product in the hands of more users.
- Details Published:

Floreo started raising capital earlier this year to get its product in the hands of more users.
Institute for Bioscience and Biotechnology Research (IBBR) Fellow Dr. Daniel Nelson (Associate Professor, Department of Veterinary Medicine, University of Maryland, College Park) is working on an innovative approach to treating bacterial disease in collaboration with Dr. Rajan Adhikari, Assistant Director of Bacteriology at Integrated BioTherapeutics (IBT), and George Mason University's Dr. Ramin Hakami (Associate Professor, School of Systems Biology and National Center for Biodefense and Infectious Diseases). The group recently received a $3M Phase II STTR award from the National Institutes of Health that will fund advancement of their novel immunotherapeutic into non-human primates, as well as optimization of a cell line for biomanufacturing the drug.
A US/Ko re an hy brid biotech run by a group of sci en tists out of Johns Hop kins just scored a megaround of $137.1 mil lion, with plans to ad vance a slate of ex per i men tal drugs held at its 3 sub sidiary op er a tions.
The state-backed tech group is also in the midst of finding a new CEO to replace George Davis, who left in July.
Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease (IBD) care. The challenge, “Transforming IBD Care: Better disease monitoring, management, and care for people with inflammatory bowel disease” focuses on innovation in IBD monitoring, condition management or care enhancements.
Virginia Bio, the statewide non-profit trade association for the life science industry, today announces that John L. Newby II is named CEO, effective August 5, 2019.
Tweet this Newby will be leaving his current role as the Commissioner of the Virginia Department of Veterans Services (VDVS), where he leads an 850-member Agency located across 50 Virginia locations, delivering employment, education, benefits, behavioral health and long term health care services to Virginia’s Reservists, Guardsmen, transitioning service members and 725,000 veterans.
Three health care-related startups based in the Richmond area have merged their operations with the goal of providing better preventative and personalized medical diagnostics.
The merger brings together Salveo Diagnostics, ImmunArray and Nudge, in what leaders of the three businesses describe as a combination “greater than the sum of its parts.”
7th Annual Pediatric Device Innovation Symposium | Pediatric Device Clinical Trials: Forging a Better Path
On September 22, 2019, one day before The MedTech Conference powered by AdvaMed, join stakeholders from the industry, government, academia and patient groups for the nation’s leading pediatric innovation symposium where we will focus on unique challenges and opportunities related to pediatric device trials. Now in its seventh year, the one-day symposium, hosted by Children’s National Health System, brings together key leaders in the device space to stimulate pediatric device innovation and bring solutions to market faster for the benefit of children everywhere. Another highlight is the 'Make Your Medical Device Pitch for Kids' competition.
Johns Hopkins University and biotech company United Therapeutics Corporation have teamed up to create a new postdoctoral fellowship in the emerging field of computational medicine.
Innovators and startup companies with devices designed to improve neonatal or NICU care now have a one-week extension until Aug. 19, 2019 to apply for the $150K "Make Your Medical Device Pitch for Kids!" competition funded by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI).
Investment in healthcare artificial intelligence startups and companies focused on mental health and wellness soared in the second quarter as both sectors hit funding highs, according to a new report.
With technological advancement occurring at an increasingly breakneck pace, it's natural the number of life science and technology innovation clusters is growing as well. These clusters result from the increasing recognition that innovators do not perform at their best in widely dispersed buildings. Instead, they gain most from highly specialized facilities and collaborative ecosystems that foster cross-fertilization of ideas.
The therapies saved roughly 90 percent of the patients who received them early in the course of infection. Doctors hope patients will seek out the cures, ending the outbreak.
Rising drug prices and ever-increasing costs are two of the most debated subjects in healthcare. The Centers for Medicare and Medicaid Services (CMS) predicts (PDF link) that we will see 6.1 percent annual prescription drug cost increases until at least 2027. CMS expects healthcare spending as a whole to grow by 5.7 percent per year for the same timeframe.
Our map shows the top VC investing in tech companies in each state, from 500 Startups in California to Lerer Hippeau in New York.
Researchers have been able to coax human breast cancer cells to turn into fat cells in a new proof-of-concept study in mice.
To achieve this feat, the team exploited a weird pathway that metastasising cancer cells have; their results are just a first step, but it's a truly promising approach.
Thank you to BioHealth Innovation, Inc. for this incredible experience. I learned so much from these brilliant minds, and look forward to an ongoing relationship.
Applications Due September 5
The Commercialization Readiness Pilot (CRP) Program is now open and accepting applications for the September 5th NIH SBIR/STTR receipt date. NHLBI will accept applications via PAR-19-333, PAR-19-334, and PAR-19-335 from small businesses that have had an active NHLBI SBIR or STTR Phase II or Phase IIB award within the last 36 months.
This opportunity provides up to $300,000 (PAR-19-334) or $500,000 (PAR-19-333, PAR-19-335) to support technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts including:
Contact NHLBI Small Business Program Coordinator Mike Pieck (This email address is being protected from spambots. You need JavaScript enabled to view it.) with questions.
Bayer said today it has agreed to acquire BlueRock Therapeutics for up to $600 million in a deal designed to catapult the buyer into leadership in cell therapies, nearly three years after joining with healthcare investment firm Versant Ventures to launch the company.
This just in: Maryland’s internet is the least likely to cut out right at the juicy scene in ‘The Bachelor’. According to web service provider assessment group Highspeedinternet.com, Maryland has the fastest internet speed in the country.
While medical device innovation is quite active—at the university level, within incubators, and even in the R&D labs of established firms—there is a substantial lack of products being developed for younger patients. Since pediatric devices have a limited patient base due to most children being relatively healthy (of course, a positive factor), it’s not a focus for a great number of companies as it does not offer the promise of a substantial financial return.
The amount of deals and dollars invested in healthcare is hitting near record highs for the first half of 2019 with $26.9 billion poured into healthcare companies over 2,258 deals around the world, according to CB Insights’ Global Healthcare Report.
That represents a slight uptick from the first half of 2018 where $26.5 billion was invested over 2,223 deals.
Everyone knows how important funding is for starting a venture, whether you are building a small business or high-growth tech startup. The capital needs of a venture change along with the venture’s stage — early-stage ventures might need help with product development costs, while established companies may need funding to expand to a new location or market segment.
RoosterBio, Inc., a Frederick, MD-based human mesenchymal stem/stromal cell (hMSC) biomanufacturing company, raised in excess of $15m in an initial Series B financing.
The round was led by Dynamk Capital, with participation from existing and new investors. The Series B final round is expected to close with additional investors by the end of August, totaling approximately $22m raised.
The growing number of private biopharma and diagnostic/therapeutic technology company financings completed in recent months masks an overall year-over-year decrease in the total value of those deals.
On Thursday, August 22nd from 4-6:00 pm there will be an open house for the fall courses in the “Advanced Studies in Technology Transfer” program at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH in the FAES Academic Center in NIH Building 10 in Bethesda, MD. For the semester beginning on Monday, September 9th there will be 9 courses available for the program given in either Rockville or Bethesda:
More details can be found in the new 2019-20 course catalog (www.faes.org) with online registration for classes available. The Advanced Studies in Technology Transfer is an open enrollment program with class credits transferable into various graduate degree programs at the University of Maryland University College (UMUC) Graduate School and the University of Maryland Baltimore County (UMBC).
Technology Transfer Scholarships
FAES offers a limited number of partial tuition-remission scholarships for self-funding students. For deadlines and details on how to apply visit https://faes.org/tuition-and-funding .
Also as Department Chair, I’m happy to assist with any questions you might have about the program or individual courses.
Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade – accurately, it turns out. Paul Graham predicted that there would be way more startups, that they’d be cheaper to start, that new kinds of investors would fund them, that founders would be more technical, and that founders would keep control of their companies. All of those seem to have come true.
Facility Logix, a leading life science consulting firm, has hired two new Associate Project Managers: Jocaro L. Dodd and Wayne Mitchell. The new Associate Project Managers will be instrumental in addressing the facility-related needs of the firm’s Owner’s Representation and Project Management clients.
Canton-based VitusVet, which built a health IT platform for vets, received investment from Nationwide Insurance as the company’s team continues to grow.
Joshna Seelam is closing in on her target.
The VCU graduate student is one of three members of Kilo Medical Solutions, a Richmond medical device startup that’s getting ever closer to launch.
County Executive Marc Elrich and Council Vice President Sidney Katz are embarking on a multi-pronged joint initiative: 4Business – Benchmarking to Be the Best for Business.
The objective is to engage the local business community in a grassroots campaign to assist businesses to locate, grow and prosper in Montgomery County.
Was your credit card unexpectedly rejected? Or have you spotted unfamiliar charges on your bank statement? These are just a couple signs of potential identity theft. (Source: Federal Trade Commission)
Once you realize your identity has been compromised, you need to act fast. But don’t panic; this guide will walk you through each step you need to take to be sure you recover as quickly as possible.
The gene therapy company has made three distinct moves over the past week that reinforce its intention to get products to market after a decade in business.
GlaxoSmithKline and Pfizer have finally closed on a multibillion-dollar merger that combined their consumer healthcare businesses, creating the world’s largest over-the-counter business.
The pharmaceutical giants — which own household names like Advil and Tums — announced the joint venture back in December 2018.
A venture capital firm formed by a founder of one of the first companies to win Food and Drug Administration approval for a cell therapy for cancer closed a new fund worth more than half of $1 billion.